Evaluating Dose-response of Cataract Induction in Radiotherapy of Head and Neck Cancers Patients.
Cataract
Eye Lens Absorbed Dose
Head and Neck Cancers
Radiation Dosage
Radiotherapy
Journal
Journal of biomedical physics & engineering
ISSN: 2251-7200
Titre abrégé: J Biomed Phys Eng
Pays: Iran
ID NLM: 101589641
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
10
09
2017
accepted:
16
11
2017
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
11
2
2021
Statut:
epublish
Résumé
Head and neck cancers are currently the most common types of cancers. 3D-conformal radiation therapy is the most common dose delivery technique for head and neck cancers. Eye Lens is a radio sensitive structure and cataract formation as a visual disorder associated with exposure to ionizing radiation which is documented. Determining the radiation dose to eye lens during head and neck radiography and estimating the probability of cataract induction are essential. This experimental study was performed on 14 patients with head and neck cancers through experimental study analysis. The maximum opacity of the eyes lens were measured by pentacam Overall, 28 lenses were studied. Statistical one sample K- S test proved normality of obtained data. Using repeated measures test, the relation before and 3 months after radiotherapy, as well as the relationship before and 6 months after radiotherapy proved a significant relationship. The opacity caused by radiation in eyes is a non-statistical and linear-quadratic response curve with no threshold. This opacity can also appear within 3 months after completion of radiation therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Head and neck cancers are currently the most common types of cancers. 3D-conformal radiation therapy is the most common dose delivery technique for head and neck cancers. Eye Lens is a radio sensitive structure and cataract formation as a visual disorder associated with exposure to ionizing radiation which is documented.
OBJECTIVE
OBJECTIVE
Determining the radiation dose to eye lens during head and neck radiography and estimating the probability of cataract induction are essential.
MATERIAL AND METHODS
METHODS
This experimental study was performed on 14 patients with head and neck cancers through experimental study analysis. The maximum opacity of the eyes lens were measured by pentacam
RESULTS
RESULTS
Overall, 28 lenses were studied. Statistical one sample K- S test proved normality of obtained data. Using repeated measures test, the relation before and 3 months after radiotherapy, as well as the relationship before and 6 months after radiotherapy proved a significant relationship.
CONCLUSION
CONCLUSIONS
The opacity caused by radiation in eyes is a non-statistical and linear-quadratic response curve with no threshold. This opacity can also appear within 3 months after completion of radiation therapy.
Identifiants
pubmed: 33564635
doi: 10.31661/jbpe.v0i0.834
pii: JBPE-11-1
pmc: PMC7859376
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9-16Informations de copyright
Copyright: © Journal of Biomedical Physics and Engineering.
Références
Cancer Metastasis Rev. 2005 Jan;24(1):9-17
pubmed: 15785869
Ann ICRP. 2007;37(2-4):1-332
pubmed: 18082557
Radiat Res. 2007 Oct;168(4):404-8
pubmed: 17903036
Int J Radiat Oncol Biol Phys. 1984 Jul;10(7):957-64
pubmed: 6378850
Nat Rev Genet. 2003 Nov;4(11):876-88
pubmed: 14634635
Int J Radiat Biol. 2004 May;80(5):339-45
pubmed: 15223766
Radiat Res. 1999 Aug;152(2):190-5
pubmed: 10409329
J Radiol Prot. 2012 Jun;32(2):147-54
pubmed: 22555212
Radiat Res. 2007 Feb;167(2):233-43
pubmed: 17390731
Health Phys. 2006 Feb;90(2):154-60
pubmed: 16404173
J Radiat Res. 1991 Mar;32 Suppl:283-93
pubmed: 1762117
Bull N Y Acad Med. 1983 May;59(4):372-92
pubmed: 6575847
Bull Soc Belge Ophtalmol. 2002;(283):19-25
pubmed: 12058483
Radiat Res. 2009 Jul;172(1):1-9
pubmed: 19580502
Ophthalmol Clin North Am. 2006 Dec;19(4):415-25
pubmed: 17067897
Lancet. 2005 Feb 12-18;365(9459):599-609
pubmed: 15708105
Am J Roentgenol Radium Ther Nucl Med. 1957 May;77(5):759-85
pubmed: 13411351
Surv Ophthalmol. 1988 Nov-Dec;33(3):200-10
pubmed: 3068822
Br J Ophthalmol. 1997 Apr;81(4):261-6
pubmed: 9215051
Oral Oncol. 2006 Feb;42(2):184-9
pubmed: 16256417